Diabetes Treatment and Management
Open access
Peer reviewed
Scollr summary
What this paper is about
Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience.
Full abstract
Read the full abstract
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and cardiovascular death), and the risk of admission to or treatment within hospital for heart failure. These drugs reduce albuminuria and slow the decline in estimated glomerular filtration rate over time, therefore delaying or preventing kidney failure. Furthermore, GLP-1 receptor agonists (eg, liraglutide and semaglutide) and the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist tirzepatide have been approved for treatment of obesity, with clinical trials establishing benefits for various obesity-related conditions: prevention of type 2 diabetes; risk for major adverse cardiovascular events; heart failure, especially with preserved ejection fraction; regression of steatosis and prevention of fibrosis in steatotic liver disease; and symptomatic improvements in obstructive sleep apnoea and knee osteoarthritis. Current developments include the exploration of novel indications (eg, neurodegenerative diseases and substance use disorders) with suggestive evidence of efficacy, and the development of small-molecule GLP-1 receptor agonists for oral treatment to improve convenience. Dual (ie, GLP-1-glucagon and GLP-1-amylin) and triple (ie, GIP-GLP-1-glucagon) receptor agonists activating multiple receptors promise greater efficacy than mono-agonists, especially for weight loss. However, some clinical development programmes have a high burden of adverse gastrointestinal events, and dose-escalation regimens should be optimised to reach acceptable tolerability.
Direct answer
What can I do from this paper page?
Use this page to scan "GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Diabetes Treatment and Management research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Nauck2026receptor,
title = {GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits},
author = {Michael A Nauck and KATHERINE R. TUTTLE and Matthias H. Tschöp and Matthias Blüher},
journal = {The Lancet},
year = {2026},
doi = {10.1016/s0140-6736(25)02105-1},
url = {https://doi.org/10.1016/s0140-6736(25)02105-1}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Diabetes Treatment and Management research papers?
Follow Diabetes Treatment and Management research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app